Kim FS, Patel PV, Stekol E, et al. - Long-term efficacy of ustekinumab (UST), a human monoclonal antibody against interleukin-12 and 23, was evident in pediatric patients with Crohn disease (CD), with no observed safety concerns. Dose adjustment could aid in achieving clinical remission.

• This study included 38 pediatric patients with CD treated with UST between January 1, 2016 and December 31, 2019.

• At last follow-up, 84.2% of patients continued taking UST for a median span on UST of 62.1 weeks, and clinical remission was achieved by 60.5%.

• Abbreviated pediatric CD activity index scores, clinical remission rates, albumin, and hematocrit, all improved significantly, and there were no significant adverse events in 89.5% of patients.

• Findings were similar in patients who needed dose adjustment, including 61.1% achieving clinical remission, and in those with perianal disease, including 38.5% attaining clinical remission.